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Human sperm assay (HSA) is a preferred in house quality control and proﬁciency test (PT) practiced in fertility laboratories.
HSA is performed over varying durations, apparently without following set criteria. To better understand the assay time required
for reprotoxicity testing in embryo culture media, we compared American-Association-of-Bioanalysts-(AAB-) administered HSA
data to our own assay performed using PT samples obtained from AAB. Participating laboratories were required to culture sperm
for 48 hours to determine media acceptability. Conclusions drawn from 48- and 24-hour observations were the same, suggesting
that HSA could identify reprotoxic media in less time than required by AAB. Our assay revealed that changes in motility grade in
adulteratedmediaaresigniﬁcantlydiﬀerentfromthoseincontrolmedia.Furthermore,gradechangescanbeidentiﬁedearlierthan
diﬀerences in motility loss between samples. Analyzing motility and motility quality together provides a method for establishing
an optimal time for HSA.
1.Introduction
Quality control (QC) is an essential component of a
successful human in vitro fertilization (IVF) program. The
success of IVF depends critically on the quality of the prod-
ucts used in the laboratory procedures. The reprotoxicity
testing of reagents, media, and consumables utilized in the
fertility laboratory is therefore essential [1–4]. Accordingly,
numerous bioassays have emerged over time for evaluating
procedural quality [5–8].
Among these bioassays, the human sperm assay (HSA)
has been an integral part of IVF since its inception. Edwards
and Steptoe, the 2 pioneers of human IVF, utilized HSA for
testing the suitability of the solutions and materials used in
the ﬁrst successful IVF pregnancy in the world [1, 9]. The
sperm assay allowed them to detect factors that adversely
aﬀected the growth of human embryos in vitro, thus oﬀering
anopportunityforoptimizingtheembryocultureconditions
[1, 8, 9]. Subsequently, many other assays have been devel-
oped utilizing mouse embryos, hamster sperm, ovarian cells,
cumulus cells, and so forth, in evaluating the quality of the
embryo culture procedures [6–11]. HSA, however, remains
one of the preferred QC methods in fertility laboratories
where it is routinely used as an in house QC test and also
as an externally administered proﬁciency test (PT).
Review of the HSA literature indicates that human sperm
bioassays are being performed over varying durations of
time [3, 12–14]. Alvarez proposed 4 hours for the sperm
stress test, while in regular sperm bioassays, assay times
of 24 to 96 hours have been used [15–20]. The American
Association of Bioanalysts (AAB), the largest PT provider
for fertility laboratories in USA, chose an assay time of
48 hours for identifying the quality of the embryo culture
media [3, 20–22]. It is possible that if an assay is extended
beyond the required time, its sensitivity and speciﬁcity can
be compromised [10, 12, 17, 23–25].2 Advances in Urology
In this study, we explored AAB-administered PT to
develop a better understanding of the time required for
HSA in AAB-set culture conditions. The AAB provides
participating laboratories with 2 media samples in each PT
event. The quality of one media is intentionally made poorer
than that of the other. The laboratories are required to
perform HSA for 48 hours to identify the media as being
of acceptable (MAQ) or unacceptable (MUQ) quality. The
purpose of this PT is for fertility laboratories to develop the
skills needed for evaluating the quality of their own media to
be used in IVF procedures. The AAB has been administering
this PT for more than 10 years. We evaluated the AAB-
compiled HSA data for the past 2 years and also performed
our own assay using a set of AAB-provided PT samples. We
are able to demonstrate that the assay time for HSA utilized
in AAB PTs is lengthy, and that evaluation of the motility
grade, along with the motility, enhances the eﬃciency of the
assay, therefore helping to optimize the assay time.
2.MaterialsandMethods
2.1. AAB-Administered PT Data on HSA. The data of
AAB-conducted PT for determining the suitability of cul-
ture media utilizing HSA was used (data from AAB:
http://www.aab-pts.org/) [20, 21]. The PT score represented
human sperm survival in the 2 culture media, labeled
embryo culture 1 (EC1) and embryo culture 2 (EC2), in each
PT event of year 2008 and 2009. There was a total of 4 events
(08 − E1, 08 − E2, 09 − E1, and 09 − E2), in each of which
EC1 and EC2 were identiﬁed either as MAQ or MUQ by
performing HSA.
More than 130 fertility laboratories across the United
States participated in the AAB-administered PT. The partic-
ipating laboratories recorded sperm motility as an indicator
of sperm survival in EC1 and EC2 at 0, 24, and 48 hours in
order to reveal the diﬀerences in their quality. The methods
used in AAB-administered HSA fall under 2 categories:
sperm culture with and without oil overlay. The laboratories
werealsorequiredtoculturespermwithandwithoutprotein
supplementation.
Statistical analysis of the AAB-compiled sperm motility
data (average±S D )i nE C 1a n dE C 2r e p o r t e db yt h e
participating laboratories (n ≥ 130) was performed to see if
the motility diﬀerence between EC1 and EC2 was signiﬁcant
at 24 and 48 hours. The 95% conﬁdence interval for the
diﬀerenceinmeansbetweenthe2mediawascalculated(EC1
versus EC2) in each PT event (08 − E1, 08 − E2, 09 − E1,
and 09 − E2). The level of signiﬁcance (alpha) was adjusted
using the Bonferroni correction to account for multiple
comparisons, and a t-test utilizing pooled variance was
used.
2.2. HSA Utilizing Motility and Motility Quality. A separate
HSA experiment of our own was performed using AAB-
provided 09-E2 PT samples. In this experiment, sperm
culture in EC1 and EC2 were established following a no oil
overlay method of culture in which sperm motility, as well as
motilityquality,wererecordedsequentiallyat0,6,12,and24
hours.
The gradient-washed sperm samples (n = 6), exhibit-
ing ≥90% motility and a motility grade predominantly
of 4, were used for the convenience of experiment. The
cultures, composed of EC1 and EC2 media of 1.0mL
volume containing 4-5 × 106/mL sperm, were established
in 5mL Falcon culture tubes (Becton and Dickinson). All
culture conditions were maintained in duplicates in a gas
(6% CO2)a n dt e m p e r a t u r e( 3 7 ◦C) controlled incubator.
Sperm motility and motility grade in the culture were
evaluated at the indicated time points by assessing aliquots
of samples in the Makler chamber following WHO cri-
teria but with a modiﬁed grading system [24, 26, 27].
The relative abundance of motile sperm exhibiting dif-
ferent motility grades (G1: nonprogressive; G2: sluggish
progressive; G3: progressive; G4: rapid progressive) was
documented.
3. Results
The AAB data that was brought under our investigation
is shown in Table 1. As evident from the motility scores
documented in Table 1, the EC1 was unacceptable (MUQ)
in PT events 08 − E1, 08 − E2, and 09 − E1, while the EC2
was MUQ in the 09-E2 event.
The motility diﬀerence between EC1 and EC2 (catego-
rized either as MAQ or MUQ) was statistically signiﬁcant
(P ≤ .05) at 24 hours as well as at 48-hour observations in
all PT events (08 − E1, 08 − E2, 09 − E1, and 09 − E2) of
years 2008 and 2009 (Figures 1 and 2). As seen in Figure 1,
the diﬀerence between MUQ and MAQ (EC1 versus EC2)
during the ﬁrst 24 hours was convincingly acceptable in
all 4 PT events (08 − E1: 51.9 ± 26.0v e r s u s7 6 .1 ± 14.8;
08 − E2: 52.2 ± 24.6v e r s u s7 5 .2 ± 16.1; 09 − E1: 40.7 ± 26.2
versus 77.6 ± 12.4; 09 − E2:7 6 .3 ± 11.5v e r s u s4 1 .8 ± 9.0).
Further, the signiﬁcant diﬀerence between EC1 and EC2 at
24 hours was revealed by both assay methods (oil overlay:
38.0±22.8v ersus73.5±14.1;nooiloverlay:49.6±22.0v ersus
77.3 ± 14.0) and independently of protein supplementation
(with protein: 47.3±22.3v e r s u s7 7 .5±13.1; without protein:
40.1 ±22.4v e r s u s7 3 .1 ±15.0).
The results of our own HSA study are shown in Figure 3.
The EC1 and EC2 were identiﬁed as MAQ and MUQ,
respectively. The presence of toxicant, as in EC2 (MUQ),
was better predicted by motility grade than by motility in
the early exposure period (6–12 hours). As seen in Figure 3,
there was a shift in motility grade composition (EC1: G4
70%,G330%versusEC2:G460%,G340%)butnotmotility
(EC1: 92 ± 4% versus EC2: 89 ± 6%) in the ﬁrst 6 hours.
Evidence of the diﬀerence between EC1 and EC2, reﬂecting
changesinmotility gradeaswellasmotility, becamestronger
at 12 hours. However, the diﬀerences in motility grade
(EC1: G4 65%, G3 35% versus EC2: G4 40%, G3 50%,
G2 10%) compared to motility (EC1: 89 ± 3% versus EC2:
82 ± 7%) were predominant. Such diﬀerence became more
pronounced between the 2 PT specimens (EC1 and EC2)
by 24 hours as evident in motility grade (EC1: G4 20%, G3
50%, G2 25%, G1 5% versus EC2: G4 5%, G3 40%, G2 50%,
G1 5%) and also in motility (EC1: 76 ± 9% versus EC2:
41 ± 13%).Advances in Urology 3
Table 1: AAB-compiled PT data on HSA from the reporting of the participating laboratories for the years 2008 and 2009. The value
represents motility (mean±SD) in respective culture conditions at speciﬁed observation points.
PT Event No. of Labs particip Method type Obs points
Culture conditions tested
EC1 EC2 EC1 EC2
Protein (+) Protein (+) Protein (−) Protein (−)
08 −E1 34 Oil overlay 0Hr 89.6 ±7.68 9 .0 ±8.28 9 .4 ±7.68 9 .5 ±7.5
08 −E1 96 No oil 0Hr 88.4 ±9.68 8 .1 ±9.78 6 .5 ±10.78 6 .1 ±11.3
08 −E1 142 Combined 0Hr 88.6 ±9.58 8 .3 ±9.78 7 .1 ±10.58 7 .0 ±10.6
08 −E2 32 Oil overlay 0Hr 89.7 ±8.48 9 .8 ±8.28 9 .0 ±10.49 0 .4 ±8.1
08 −E2 95 No oil 0Hr 88.2 ±9.08 8 .1 ±8.88 6 .6 ±10.38 6 .2 ±11.3
08 −E2 138 Combined 0Hr 88.5 ±9.28 8 .4 ±9.18 7 .1 ±10.68 7 .2 ±10.9
09 −E1 35 Oil overlay 0Hr 88.6 ±10.08 8 .6 ±10.18 9 .0 ±9.08 8 .7 ±9.9
09 −E1 97 No oil 0Hr 88.3 ±8.58 8 .4 ±8.58 7 .4 ±8.68 7 .3 ±8.9
09 −E1 140 Combined 0Hr 88.4 ±8.78 8 .5 ±8.78 7 .8 ±8.88 7 .3 ±9.5
09 −E2 33 Oil overlay 0Hr 88.3 ±12.08 9 .5 ±11.08 8 .1 ±13.08 8 .2 ±12.0
09 −E2 101 No oil 0Hr 89.6 ±7.08 9 .8 ±7.08 8 .0 ±9.08 8 .5 ±9.0
09 −E2 143 Combined 0Hr 89.2 ±9.08 8 .9 ±9.08 8 .2 ±9.08 8 .4 ±9.0
08 −E13 4 O i l o v e r l a y 2 4 H r s 5 0 .8 ±25.97 6 .4 ±11.94 5 .7 ±29.17 6 .2 ±12.6
08 −E1 94 No oil 24Hrs 57.2 ±25.47 8 .6 ±15.14 9 .4 ±25.27 3 .8 ±15.0
08 −E1 140 Combined 24Hrs 55.7 ±25.97 8 .5 ±14.24 8 .0 ±26.17 3 .6 ±15.3
08 −E23 2 O i l o v e r l a y 2 4 H r s 5 0 .8 ±29.67 7 .3 ±15.84 3 .3 ±25.96 9 .8 ±19.7
08 −E2 92 No oil 24Hrs 59.2 ±21.07 9 .2 ±13.05 1 .2 ±23.97 1 .9 ±19.7
08 −E2 135 Combined 24Hrs 56.1 ±24.17 8 .4 ±13.74 8 .3 ±25.17 1 .9 ±18.5
09 −E13 4 O i l o v e r l a y 2 4 H r s 3 4 .1 ±26.17 5 .5 ±10.32 9 .1 ±25.47 1 .2 ±12.2
09 −E1 96 No oil 24Hrs 48.5 ±25.58 1 .6 ±10.33 9 .9 ±25.67 6 .9 ±12.8
09 −E1 138 Combined 24Hrs 44.5 ±26.47 9 .4 ±11.53 6 .8 ±25.97 5 .1 ±13.2
09 −E23 2 O i l o v e r l a y 2 4 H r s 7 1 .8 ±15.02 7 .7 ±10.06 9 .5 ±15.02 1 .9 ±10.0
09 −E2 100 No oil 24Hrs 79.7 ±13.05 0 .4 ±15.07 5 .8 ±13.04 0 .6 ±14.0
09 −E2 141 Combined 24Hrs 79.0 ±12.04 5 .3 ±10.07 3 .6 ±11.03 8 .2 ±8.0
08 −E13 2 O i l o v e r l a y 4 8 H r s 2 0 .5 ±23.15 3 .0 ±24.31 4 .6 ±18.05 3 .1 ±26.9
08 −E1 91 No oil 48Hrs 32.1 ±24.46 2 .0 ±24.02 5 .6 ±22.65 7 .5 ±23.0
08 −E1 134 Combined 48Hrs 29.3 ±25.16 0 .3 ±24.22 2 .8 ±22.75 5 .9 ±23.7
08 −E23 0 O i l o v e r l a y 4 8 H r s 2 1 .3 ±21.84 9 .1 ±26.51 5 .0 ±13.74 4 .9 ±24.1
08 −E2 90 No oil 48Hrs 36.9 ±24.16 6 .3 ±19.02 7 .7 ±22.85 8 .5 ±23.3
08 −E2 130 Combined 48Hrs 32.0 ±24.46 0 .4 ±23.12 4 .4 ±22.05 5 .1 ±23.6
09 −E1 32 Oil overlay 48Hrs 9.7 ±11.05 1 .2 ±24.08 .6 ±13.14 7 .6 ±26.1
09 −E1 91 No oil 48Hrs 25.4 ±22.46 2 .2 ±23.81 6 .6 ±17.85 8 .3 ±25.9
09 −E1 131 Combined 48Hrs 22.6 ±22.35 8 .2 ±24.51 4 .8 ±17.65 4 .3 ±26.4
09 −E23 0 O i l o v e r l a y 4 8 H r s 4 9 .1+1 4 .06 .8+2 .04 3 .5+1 1 .05 .0+1 .0
09 −E2 95 No oil 48Hrs 68.4+1 4 .02 2 .7+7 .06 3 .3+1 4 .01 7 .7+6 .0
09 −E2 134 Combined 48Hrs 61.9+1 0 .02 0 .6+4 .05 6 .1+1 0 .01 4 .9+4 .0
4. Discussion
The HSA has been an integral part of fertility laboratories
for many obvious reasons. First, the assay method is user
friendly, requiring less technical skill and equipment than
other methods. Animal models like mouse embryo assay
(MEA) and hamster sperm motility assay (HSMA), the
alternatives to HSA, may be commercially available but
are expensive and labor intensive. Most importantly, when
human sperm is used, no species diﬀerences have to be taken
into account in interpreting and validating the outcome
of the test. Since the ﬁrst report of successful human IVF,
various modiﬁcations have been introduced to improve
the IVF techniques, and HSA has played a role in such
improvements [2, 9, 15]. Therefore, HSA was not only used
by the IVF pioneers, but it has also maintained a permanent
footing in IVF laboratories to this day.
The AAB, being an authorized PT provider, has been
collecting HSA data from fertility laboratories for more
than 10 years. The participating laboratories are required to4 Advances in Urology
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Figure 1: Motility in MUQ and MAQ at 24- and 48-hours
observations in the 4 consecutive PT events. The diﬀerence between
MUQ and MAQ was signiﬁcant (P<. 05) in all events at 24 hours
as well as 48 hours. MUQ at 24hours (green); MAQ at 24hours
(purple); MUQ at 48hours (Blue); MAQ at 48hoyrs (red).
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Figure 2:Acollectionof95%conﬁdenceintervalsforthediﬀerence
in mean motility between 24-hour and 48-hour observations.
perform the assay for 48 hours to fulﬁll AAB requirements.
The cost and labor required for an assay are directly related
to the assay time. The longer the assay duration, the more
expensive the assay becomes. We are able to show that HSA
values in EC1 and EC2 are signiﬁcantly diﬀerent at 24, as
well as at 48, hours in all 4PT events conducted in the years
2008 and 2009. We argue that when the diﬀerence between
Motility Motility grades
Observation
time EC1 EC2 EC1 EC2
0hrs
24hrs
6hrs
12hrs
Figure 3: Change pattern in motility (motile: olive green; non-
motile: light orange) and motility grades (G4: green; G3: yellow;
G2: blue; G1: red) in AAB-PT event 09−E2 samples (EC1 and EC2)
during sperm culture for 24 hours.
EC1 and EC2 can be conﬁdently conﬁrmed by 24hrs, then
prolonging the assay up to 48 hours is not necessary.
We further argue that the loss of motility in any
culture, even one completely free of any harmful elements
(toxicants), is expected to occur as time progresses. This
natural phenomenon of sperm motility loss in culture
may overshadow the real toxicant-induced motility loss,
producing erroneous results if the assay time is extended
beyond that actually required. It thus appears that there is
no gain in prolonging the culture for an additional 24 hours
in AAB-administered PTs.
The participating laboratories did not have an option for
evaluating motility in the culture before 24 hours in AAB-
administered PTs. It is possible that a signiﬁcant motility
diﬀerence between EC1 and EC2 may have emerged prior
to that time (24 hours) but was missed because of lack of
investigation. The preliminary results of our own bioassay
support this notion. We documented increased motility loss
inEC1comparedtoEC2at6-hourand12-hourobservations
but were unable to validate its statistical signiﬁcance because
of our small sample size. It will be worth investigating our
observation further with a larger sample size.
The evaluation of the quality of the sperm motility
(motility grade) is now a routine practice in semen analysis
[27]. We realized that such parameters will also be informa-
tiveiftheycanbeincorporatedinthebioassay.InHSMA,the
motility grade is given an equal emphasis to that of motility
[6]. However, motility grade evaluation was not given any
consideration in human sperm bioassay [6, 28, 29]. The
HSMA neither gained wide acceptance in human fertilityAdvances in Urology 5
laboratories nor inﬂuenced HSA to incorporate motility
grade evaluation. In our study, we showed that the mode
of change in motility grade (motility quality) in adulterated
media(EC2)issigniﬁcantlydiﬀerentfromthatofthecontrol
media (EC1). The onset of the diﬀerence in the motility
quality between the 2 media (EC1 and EC2) can be identiﬁed
earlier than the motility loss, as it is logical that any harmful
agent will aﬀect the motility quality ﬁrst before motility is
completely lost. Therefore, the inclusion of motility quality
evaluation in HSA will increase its sensitivity and thus
will help in identifying the diﬀerence earlier. Future HSA
studies may reﬁne motility quality evaluation so that its
incorporation in the assay can be perfected.
We must admit that motility grading in its current state
is subjective, and it is diﬃcult to give it a true quantitative
face. There may be concern about the concept of sperm
motility grade being used as a tool in sperm bioassay due to
the subjective nature of distinguishing between the various
grades. Identifying motile and nonmotile sperm is a much
more straightforward issue than distinguishing between the
v a r i o u sg r a d e so fs p e r mm o t i l i t y .H o w e v e r ,d i ﬃculty in
grading motility should not hinder the beneﬁt we can
achieve by incorporating motility grade in the assay. We
used a grading scheme of our own—which may not be
a perfect one—in placing sperm under diﬀerent motility
grades. A lot is now known about the motility characteristics
of mammalian sperm; therefore, developing a consensus
on grading motility will be easier than before. In our
view, overcoming the problem of grading motility involves
emphasizing the importance of the issue, understanding the
obstacles in quantifying the grades, and then developing
consensus on grading. It is our expectation that in the
near future, consensus will be developed toward a uniﬁed
motility grading method by utilizing the technologist’s skill
in assessing motility grade both in one’s own laboratory
and between laboratories. The existing diﬃculty in grading
motility should be conquered to obtain the beneﬁt it can
provide.
Uniquely, human sperm can remain in culture for a
lengthy time [6, 24, 30]. However, this should not be the
reasonforchoosinglongerassaytimes.Theassaytimeshould
alwaysbetheminimumtimerequiredtodetectthediﬀerence
between the control and experimental culture. The impact of
primary-target determinants may be obscured by the other
unwanted variables if the assay is prolonged. The time for a
bioassay may not be a ﬁxed one since it will vary depending
ontheconcentrationandnatureofthetoxicantinthesample
to be investigated and the assay procedure to be applied.
However, it is important to determine the assay time before
the assay is performed. Arbitrarily choosing the time may
lead to erroneous conclusions. Careful evaluation of the
dynamics of motility quality, in addition to simple motility,
can make HSA more eﬀective in determining the quality of
the test material.
5. Conclusion
Our study found that in AAB-administered PTs, the col-
lection of data at 48 hours was not necessary to identify
EC1 and EC2 since the conclusion drawn from 48 hours
observation was the same as that of 24 hours. In other
words, sperm culture for 24 hours and 48 hours revealed
the same conclusion about the quality of EC1 and EC2
media in each of the 4 consecutive PT events investigated.
Further, it was revealed that the mode of change in motility
quality is diﬀerent in adulterated media compared to the
control media, and that change can be identiﬁed earlier
than the diﬀerence in motility loss between the 2 samples.
Thus, it appears that motility and motility quality combined
can sharpen the sensitivity of the assay and, thus, can help
in determining the minimum time required for the assay.
Evaluation of motility grade along with motility seems to
strengthen the power of the human sperm bioassay. This
technique holds promise in our center and now needs to be
validatedatadditionalsites,withthehopethatitmayshorten
the time used by the AAB method.
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